References
Morton A (2017) A role for thiazide diuretic therapy in preventing bone loss, fracture and nephrolithiasis in individuals with thalassemia and hypercalciuria? Osteoporos Int. doi:10.1007/s00198-017-3922-6
Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I, Papaioannou N, Tournis S (2016) Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 27:3409–3425. doi:10.1007/s00198-016-3719-z
Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Ouellette J, Monga M (2013) Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158(7):535–543. doi:10.7326/0003-4819-158-7-201304020-00005
Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR (2007) The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos Int 18(4):479–486
Arrabal-Polo MA, Arias-Santiago S, de Haro-Muñoz T, Lopez-Ruiz A, Orgaz-Molina J, Gonzalez-Torres S, Zuluaga-Gomez A, Arrabal-Martin M (2013) Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. Urology 81(4):731–737. doi:10.1016/j.urology.2012.12.013
García-Nieto V, Monge-Zamorano M, González-García M, Luis-Yanes MI (2012) Effect of thiazides on bone mineral density in children with idiopathic hypercalciuria. Pediatr Nephrol 27(2):261–268. doi:10.1007/s00467-011-1987-6
Kruse C, Eiken P, Vestergaard P (2016) Continuous and long-term treatment is more important than dosage for the protective effect of thiazide use on bone metabolism and fracture risk. J Intern Med 279(1):110–122. doi:10.1111/joim.12397
Kruse C, Eiken P, Vestergaard P (2016) Optimal age of commencing and discontinuing thiazide therapy to protect against fractures. Osteoporos Int 27(5):1875–1885. doi:10.1007/s00198-015-3451-0
Aung K, Htay T (2011) Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev 10:CD005185. doi:10.1002/14651858.CD005185.pub2
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Dede, A.D., Trovas, G., Chronopoulos, E. et al. Response to: A role for thiazide diuretic therapy in preventing bone loss, fracture and nephrolithiasis in individuals with thalassemia and hypercalciuria?. Osteoporos Int 28, 1761–1762 (2017). https://doi.org/10.1007/s00198-017-3927-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-017-3927-1